Histology-derived gene-expression signatures predict distant recurrence-free interval and chemotherapy benefit in early breast cancer cohorts.
New Tool Predicts Breast Cancer Recurrence From Old Slides
This multi-cohort study evaluated histology-derived gene-expression signatures from routine hematoxylin and eosin slides compared with clini…
A simple AI analysis of old biopsy slides can now predict which breast cancer patients face higher risk of recurrence and who truly benefits…
Phase III trial indicates ultra-low-dose nivolumab may improve survival over chemotherapy in advanced solid tumors
A Tiny Dose of This Cancer Drug Is Outperforming Chemo
This Phase III randomized trial evaluated ultra-low-dose nivolumab against standard chemotherapy in patients with advanced solid tumors prog…
Giving a much smaller dose of a powerful cancer drug can extend life with fewer side effects, making treatment more tolerable and accessible…
Pembrolizumab Plus Paclitaxel Improves Survival in Recurrent Ovarian Carcinoma Compared to Paclitaxel Alone
New Drug Combo Extends Survival for Tough Ovarian Cancer
This randomised, double-blind phase 3 study evaluated pembrolizumab plus paclitaxel versus placebo plus paclitaxel in 643 female participant…
This new combination offers a meaningful survival boost for women with recurrent ovarian cancer that has become resistant to standard treatm…
Neoadjuvant Chemoimmunotherapy Alters Tumor Microenvironment in Esophageal Cancer
Combination therapy may help overcome resistance in esophageal cancer.
This Phase 3 RCT in 55 patients with locally advanced esophageal squamous cell carcinoma compared neoadjuvant chemotherapy alone versus comb…
A small trial suggests combination therapy might help overcome resistance in esophageal cancer by targeting specific immune cells.
High-dose dexamethasone during chemotherapy shows no significant cortisol changes in breast cancer.
Chemotherapy Steroids May Not Shut Down Your Body’s Stress System
This prospective pilot study included 47 women with breast cancer receiving paclitaxel and dexamethasone. Morning serum cortisol and adrenoc…
This small study suggests that the body’s natural ability to make stress hormones might stay intact during certain chemotherapy regimens, ea…
Case report and literature review on concurrent t-AML and LNTB treated with chemoimmunotherapy
Two Rare Diseases Strike After Lung Cancer Treatment
This case report and literature review describes the management of a 54-year-old male with locally advanced lung squamous cell carcinoma, th…
A lung cancer patient treated with chemo and immunotherapy developed two rare diseases simultaneously: a new blood cancer and tuberculosis.
Early study of CDP1 plus chemotherapy showed promising activity and manageable safety in advanced penile cancer.
New Drug Combo Shrinks Advanced Penile Cancer Tumors
This prospective phase 1 study evaluated the safety and antitumor activity of CDP1 monotherapy or in combination with standard chemotherapy …
A new drug combo shrinks advanced penile cancer tumors, offering fresh hope for patients with rare, hard-to-treat disease.
Case report suggests grade 3 ICI-induced inflammatory arthritis may correlate with sustained response to tislelizumab in advanced head and neck carcinoma.
Could a painful joint flare actually signal that cancer treatment is working long-term?
This case report and literature review describes a single patient with advanced unknown primary carcinoma of the head and neck receiving mai…
A patient with advanced head and neck cancer stayed in complete remission for over a year after joint pain from treatment forced doctors to …
Sequential paclitaxel-palbociclib showed no difference in ORR versus reverse sequence in ER+/HER2- breast cancer.
New Test Predicts Who Needs Chemo in Breast Cancer
This randomized phase II trial evaluated sequential administration of paclitaxel and palbociclib with endocrine therapy in patients with ER+…
Doctors now have a way to spot patients who can skip chemo and go straight to safer hormone treatment.
Oral paclitaxel shows similar efficacy to IV paclitaxel in phase II metastatic breast cancer trial
Can an oral pill match the power of standard IV chemo for advanced breast cancer?
A phase II randomized trial of 72 patients with HER2-negative recurrent or metastatic breast cancer found oral paclitaxel (DHP107) had an ob…
An oral breast cancer pill matched IV chemo in stopping tumor growth while sparing patients from nerve damage and hair loss.
Losartan reduces incidence and delays onset of paclitaxel-induced peripheral neuropathy in women with early-stage breast cancer.
Losartan may reduce nerve pain from breast cancer chemotherapy in small trial
This single-center, open-label randomized controlled trial enrolled 89 women with early-stage breast cancer scheduled for weekly paclitaxel.…
A common blood pressure drug called losartan significantly reduced nerve pain and improved quality of life for women receiving breast cancer…
Nivolumab with chemotherapy and bevacizumab shows improved 4-year survival in advanced nonsquamous NSCLC
Nivolumab combination shows long-term survival benefit in advanced lung cancer trial
A Phase III randomized controlled trial of 550 patients with advanced nonsquamous NSCLC found nivolumab with carboplatin, paclitaxel, and be…
Adding nivolumab to standard lung cancer treatment helped patients live longer, with 34.7% surviving four years compared to 22.1% on placebo…